Systemic sclerosis (SSc, or scleroderma), is a chronic, progressive, autoimmune disease characterized by inflammation and fibrosis of connective tissues throughout the body, including the skin and internal organs. SSc that occurs in the lungs is called SSc-related interstitial lung disease (SSc-ILD).
We are investigating whether an investigational drug, called efzofitimod, can improve (or be an effective form of treatment for) the skin and lung effects caused by SSc-ILD. The clinical trial investigating efzofitimod for the treatment of SSc-ILD is called the EFZO-CONNECT™ Study.
If you are interested in taking part in this clinical trial for SSc-ILD, we are looking for people who: